Michelle J. Yang

Michelle J. Yang

Auto-generated profile, based on publicly available information

Michelle J. Yang

University of Utah, Department of Pediatrics, Division of Neonatology, Salt Lake City, Utah, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2020 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MYMichelle J. Yang
Michelle J. Yang
SFStephen Fenton
Stephen Fenton
KRKatie Russell
Katie Russell
CYChristian Con Yost
Christian Con Yost
BYBradley A. Yoder
Bradley A. Yoder

1 February 2019 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MMMichelle Mears
Michelle Mears
MYMichelle Yang
Michelle Yang
BYBradley A. Yoder
Bradley A. Yoder
Objective Pulmonary hypertension with left ventricular dysfunction commonly occurs in congenital diaphragmatic hernia (CDH). Milrinone, a phosphodiesterase-III inhibitor with lusitropic and vasodilator effects, is used in up to 30% of CDH infants across the United States. No randomized trials have tested the efficacy or safety of milrinone in CDH neonates. Study Design We performed a paired retrospective analysis of CDH infants to assess the efficacy of milrinone treatment (N = 24 pairs). Efficacy was assessed by change in oxygenation index (OI) and calculated pulmonary artery pressure (PAP). We evaluated safety on the basis of risks factors such as nonoperative bleeding, dysrhythmia, hypokalemia, and thrombocytopenia. Results The median age of milrinone initiation was 18 hours (interquartile range [IQR]: 9–38) and the median duration was 127 hours (IQR: 95–194). PAP did not change from the baseline of 49 ± 11 mm Hg (milrinone) and 53 ± 11 mm Hg (no milrinone; p = 0.327). Baseline OI was 9.6 ± 6.5. There was a similar decrease in OI (median [IQR]; milrinone: 58% [16–74]; vs. no milrinone: 65% [50–71]; p = 0.221 between groups; p < 0.005 within groups). Baseline left ventricle measurements were similar. Both groups showed significant improvement over time. No adverse events were noted. Conclusion In OI-matched untreated neonates with mild-to-moderate CDH, milrinone use was associated with neither improved OI, PAP, or left ventricular measurements, nor adverse events. Study limitations warrant prospective randomized controlled trials.

31 January 2022 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
KCKyley J. Cox
Kyley J. Cox
MYMichelle J. Yang
Michelle J. Yang
SFStephen Fenton
Stephen Fenton
KRKatie W. Russell
Katie W. Russell
CYChristian C. Yost
Christian C. Yost
BYBradley A. Yoder
Bradley A. Yoder

17 February 2025 in The Journal of Pediatrics
Verified
Journal Article
Closed access
MYMichelle J. Yang
Michelle J. Yang
RCRyan J. Carpenter
Ryan J. Carpenter
KRKatie W. Russell
Katie W. Russell
SFStephen J. Fenton
Stephen J. Fenton
CYChristian C. Yost
Christian C. Yost
BYBradley A. Yoder
Bradley A. Yoder

19 August 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
AKAnastasia M. Kahan
Anastasia M. Kahan
SGSommer L. Glasgow
Sommer L. Glasgow
BYBradley A. Yoder
Bradley A. Yoder
MYMichelle Yang
Michelle Yang
CYChristian C. Yost
Christian C. Yost
KRKatie W. Russell
Katie W. Russell
Infants with congenital diaphragmatic hernia (CDH) have varying degrees of pulmonary hypoplasia leading to cardiopulmonary derangements such as pulmonary hypertension. Extracorporeal membranous oxygenation (ECMO) can be necessary for survival in some patients. Our institution implemented a change in the NICU critical care management guideline for neonates with CDH in 2016. Indications for ECMO remained the same in the revised guideline. This study evaluated survival and surgical outcomes in CDH patients who underwent repair before and after this guideline change. Using an internal institutional registry, we identified a retrospective cohort of all CDH patients treated at our institution between January 2003 and December 2024. Patients were stratified based on year of birth before 2016 or 2016 and after. A retrospective chart review was conducted to extract primary and secondary outcome variables, which were analyzed using bivariate comparisons. A retrospective cohort of 389 patients with CDH was identified. Two hundred twenty-nine patients were treated before 2016, and 160 during or after 2016. ECMO was performed on 71 (31.0%) patients prior to 2016 and 15 (9.4%) patients during or after 2016 (p<0.001). ECMO runs and repairs on ECMO significantly decreased for patients with the most severe defect sizes (C, D). Survival was not significantly different for A, B, or C defects and was significantly improved in the most severe defects (D) (90.9% vs 42.9%, p<0.001) after the guideline change. Complications from ECMO, massive bleeding events, and thrombosis were not statistically different between time points. Changes in clinical management guideline, but not indications for ECMO, resulted in fewer ECMO runs and fewer CDH repairs on ECMO. Overall survival improved, including a significant improvement in survival for the most severe defect subgroup (D). ECMO complications, bleeding, and clotting were not different between groups, indicating that the risks of ECMO were not affected by the guideline changes. IV.

25 May 2024 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MYMichelle J. Yang
Michelle J. Yang
TETanner S. Ellsworth
Tanner S. Ellsworth
PWPaula J. Woodward
Paula J. Woodward
AKAnne M. Kennedy
Anne M. Kennedy
SFStephen Fenton
Stephen Fenton
BYBradley A. Yoder
Bradley A. Yoder